JCARH125

· Juno Therapeutics, a Subsidiary of Celgene

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JCARH125, covering 2024-05-24 to 2024-05-24. Get the full timeline:

Most recent: Clinical Trial Update: Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]

See pricing